NasdaqCM - Nasdaq Real Time Price
USD
Citius Oncology, Inc. (CTOR)
0.5540
+0.0245
(+4.63%)
At close: October 30 at 4:00:01 PM EDT
0.5536
-0.0004
(-0.07%)
After hours: October 30 at 5:35:12 PM EDT
Key Executives
Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Leonard L. Mazur
|
CEO, President & Executive Chairman | 166.25k | -- | 1945 |
|
Mr. Myron Z. Holubiak
|
Secretary & Executive Vice Chairman | 450k | -- | 1947 |
|
Dr. Myron S. Czuczman M.D.
|
Executive VP & Chief Medical Officer | 225k | -- | 1960 |
|
Mr. Jaime Bartushak
|
CFO & Treasurer | -- | -- | 1968 |
Citius Oncology, Inc.
11 Commerce Drive
First Floor
Cranford, NJ 07016
United States
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
Corporate Governance
Citius Oncology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of
Institutional Shareholder Services (ISS)
Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
June 3, 2026 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
